心力衰竭治疗新策略x(芪苈基础与临床证据2015年络病会).pptVIP

;CAD Hyp CM Valv;慢性心力衰竭治疗模式的历史沿革;; Primary Outcomes of ACEI in HF; Primary Outcomes of β Blockers in HF; Primary Outcomes of MRAs in HF;一、改善预后的三种药物—“金三角” （Ⅰ类) 1、ACEI/ARB（I类，A级） 2、β-受体阻滞剂（I类，A/B级） 3、醛固酮受体拮抗剂（I类，A/B级） 二、改善症状的药物 1、利尿剂（新型利尿剂-托伐普坦）（I类，C级） 2、地高辛(Ⅱa/b类，B级) 3、伊伐布雷定(IIa/b类，B/C级) 4、其他药物 中国心力衰竭诊断和治疗指南2014 ;;;;;J Am Coll Cardiol. 2013;62(12):1065-1072.?;;Study Design;Result：demographic data (1) ;Result：demographic data (2);Medications;;NYHA Functional Classification Results;; The Percent Change in the MLHFQ Scores from Baseline through 12 Weeks of Follow-up;Composite cardiac events;Adverse Events;;;基础研究证据;Part I: Traditional Chinese Medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice;QLQX improves cardiac function and preserves cardiomyocyte architecture; QLQX decreases cardiac fibrosis; QLQX attenuates cardiac apoptosis;QLQX improves cardiac function and survival rate AMI via increasing PPARγ;QLQX attenuates cardiac fibrosis and apoptosis via PPARγ;QLQX provides beneficial effects in remodeling phase;临床意义 作为预防心肌梗死后心室重构导致心衰的治疗策略之一？（B阶段）（RAS/BB/Ald）;Part II: Qiliqiangxin protects against cardiac ischemia-reperfusion injury via mTOR pathway;A.;;Figure 2;Figure 3;细胞免疫荧光;A;;A;A;LC3A/B I LC3A/B II;Akt (pSer 473);;Qiliqiangxin in Heart FailUre：AssESsment of Reduction in MorTality ;Study Design;慢性心力衰竭治疗药物历史沿革;